Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

BMC Gastroenterology

Table 1 Annual cost per advanced therapy regimen^a (WAC)

Advanced therapy	Cost, US$ [16]			NNT, remission [5]		Cost per remission, US$
Advanced therapy	Induction period	Maintenance period	Total	Induction period	Maintenance period	At 52 weeks
Tofacitinib 10 mg PO BID^b	9204	55,221	64,425	6.7	2.6	205,240
Tofacitinib 5 mg PO BID^b	9204	55,221	64,425	6.7	3.4	249,417
Infliximab 5 mg/kg IV Q8W^c	14,536	29,072	43,608	5.0	6.7	267,463
Vedolizumab 300 mg IV Q8W^d	22,259	44,518	66,777	9.2	3.6	365,050
Golimumab 100 mg SC Q4W^e	18,170	72,680	90,850	8.3	5.9	579,622
Adalimumab 40 mg SC Q2W^f	17,905	71,618	89,523	17.5	6.1	750,200
Ustekinumab 90 mg SC Q8W^g	5277	145,145	150,422	6.3	5.2	787,998

BID twice daily, IV intravenous, NNT numbers needed to treat, PO by mouth, Q2W every 2 weeks, Q4W every 4 weeks, Q8W every 8 weeks, SC subcutaneous, US$ United States dollars, WAC wholesale acquisition cost
^aHeadings reflect induction- and maintenance-labeled dosing per patient per year
^bInduction regimen: 10 mg twice daily for at least 8 weeks
^cInduction regimen: 5 mg/kg at 0, 2, and 6 weeks
^dInduction regimen: 300 mg at 0, 2, and 6 weeks
^eInduction regimen: 200 mg at week 0, followed by 100 mg at 2 weeks
^fInduction regimen: 4 injections in 1 day or 2 injections per day for 2 consecutive days
^gInduction regimen: Single dose using weight-based dosing (260 mg for up to 55 kg, 390 mg for > 55 kg to 85 kg, 520 mg for > 85 kg)

ISSN: 1471-230X